(2R,3S,5R)-2-[(6-amino-5-nitropyrimidin-4-yl)amino]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,5R)-2-[(6-amino-5-nitropyrimidin-4-yl)amino]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C9H13N5O6
• 分子量: 287.23
• InChiKey: OHEMBWZZEKCBAS-DTUHVUQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  180
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• NUCLEOSIDE ANALOGUES TO INHIBIT THE MAIN PROTEASE OF A CORONAVIRUS
  申请人：Institut de Recherche en Semiochimie et Ethologie Appliquée

  公开号：EP3912628A1

  公开（公告）日：2021-11-24

  The present invention is directed to nucleoside analogues to inhibit the main protease of a coronavirus. In particular the present invention relates to a composition comprising (i) a compound selected from the group consisting of clitocine, a pharmacophore for clitocine, tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or an acceptable salt thereof, and (ii) a pharmaceutically acceptable vehicle, a carrier, an excipient or a diluent, for use in the prevention and/or the treatment of an infection by a virus from the Coronaviridae family or an illness related to such infection, in a host, in particular a mammalian host.

  本发明涉及抑制冠状病毒主要蛋白酶的核苷类似物。特别是本发明涉及一种组合物，该组合物包含(i) 选自以下组别的化合物：氯妥昔、氯妥昔的药代物、同分异构体、中间体、外消旋体、对映体、非对映体或其混合物，或其可接受的盐、和 (ii) 一种药学上可接受的载体、载体、赋形剂或稀释剂，用于预防和/或治疗宿主，特别是哺乳动物宿主受冠状病毒科病毒感染或与这种感染有关的疾病。
• Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A
  申请人：Pe'ery Tsafi

  公开号：US20140206637A1

  公开（公告）日：2014-07-24

  Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
• INHIBITION OF NONSENSE MEDIATED MRNA DECAY BY DRUGS THAT PREVENT HYPUSINATION OF EUKARYOTIC INITIATION FACTOR 5A
  申请人：Pe'ery Tsafi

  公开号：US20170319612A9

  公开（公告）日：2017-11-09

  Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
• US9849146B2
  申请人：——

  公开号：US9849146B2

  公开（公告）日：2017-12-26